



Fetal Optimization During Maternal Sepsis

SFOAI Varmote 2023

Skåvsjöholm

Lawrence C. Tsen, MD

Department of Anesthesiology, Perioperative &
Pain Medicine, Brigham & Women's Hospital
Associate Professor of Anaesthesia
Harvard Medical School



No Disclosures
Movie "Rango"



Maternal Sepsis Fetal Optimization


- **D**efinitions
- **I**dentify **R**isks
- **T**herapies

Definition

Dellinger RP, et al. Surviving Sepsis Campaign, CCM 2023

No universally accepted definition in obstetric practice

Puerperal sepsis, fever, infection, pyrexia; genital tract sepsis; intrapartum septic pyrexia, infection; maternal sepsis, pyrexia, fever




Definition

Dellinger RP, et al. Surviving Sepsis Campaign, CCM 2023
Shah AD, et al. UK NIH Critical Care Collaborative 2021

No universally accepted definition in obstetric practice

Puerperal sepsis, fever, infection, pyrexia; genital tract sepsis; intrapartum septic pyrexia, infection; maternal sepsis, pyrexia, fever



Definition

Dellinger RP, et al. Surviving Sepsis Campaign, CCM 2023
Stephens AJ, et al. Maternal Sepsis Guidelines, AJ Perinat 2023

No universally accepted definition in obstetric practice

Puerperal sepsis, fever, infection, pyrexia; genital tract sepsis; intrapartum septic pyrexia, infection; maternal sepsis, pyrexia, fever

Early Goal Directed Therapy

- CVP + SVC Oxygen Saturation (not supported)
- Early Resuscitation

Fluids

- Crystalloid to Albumin to Balanced Crystalloid
- Downgraded 30 mL/kg (not supported)

Steroids

- Hydrocortisone 200 mg/d IV to subtle against to favor

Maternal Sepsis and Septic Shock

Definitions, Criteria and Tools Differ

Management Recommendations Similar

Sepsis Criteria

systemic inflammatory response syndrome (SIRS)
 quick sequential (sepsis-related) organ failure assessment (qSOFA)
 maternal early warning (MEW) criteria

Table 3. Sensitivity and Specificity of Criteria for Sepsis				
Criteria	N (%) Sepsis Cases	N (%) Controls	Sensitivity (95% CI)	Specificity (95% CI)
SIRS^a				
WBC <4 or >12	38 (74.5)	62 (41.1)	0.75 (0.60–0.86)	0.59 (0.51–0.67)
HR >90	49 (96.1)	104 (55.3)	0.96 (0.87–1.00)	0.45 (0.37–0.52)
RR >20	28 (62.2)	18 (9.9)	0.62 (0.47–0.76)	0.90 (0.85–0.94)
T <36°C or >38°C	33 (68.7)	52 (28.7)	0.69 (0.54–0.81)	0.71 (0.64–0.78)
T >38 or <36 and HR >90	33 (68.8)	33 (18.2)	0.69 (0.54–0.81)	0.82 (0.75–0.87)
T >38 or <36 and RR >20	23 (53.5)	7 (4.0)	0.53 (0.38–0.69)	0.96 (0.92–0.98)
T >38 or <36 and WBC >12 or <4	27 (56.3)	14 (9.8)	0.56 (0.41–0.71)	0.90 (0.84–0.95)
HR >90 and RR >20	28 (62.2)	15 (8.3)	0.62 (0.47–0.76)	0.92 (0.87–0.95)
HR >90 and WBC >12 or <4	36 (70.6)	32 (21.3)	0.71 (0.56–0.83)	0.79 (0.71–0.85)
RR >20 and WBC >12 or <4	20 (44.4)	6 (4.2)	0.44 (0.30–0.60)	0.96 (0.92–0.98)
Any 2 SIRS	40 (93.0)	51 (36.7)	0.93 (0.81–0.99)	0.63 (0.55–0.71)
qSOFA^a				
RR ≥22	28 (62.2)	17 (9.4)	0.62 (0.47–0.76)	0.91 (0.85–0.94)
SBP ≤100 mm Hg	26 (55.3)	76 (40.4)	0.55 (0.40–0.70)	0.60 (0.52–0.67)
Neurological changes	17 (37.8)	0	0.38 (0.24–0.53)	1.00 (0.98–1.00)
RR ≥22 and SBP ≤100 mm Hg	14 (33.3)	9 (5.0)	0.33 (0.20–0.50)	0.95 (0.91–0.98)
Any 2 qSOFA	19 (50.0)	9 (5.0)	0.50 (0.33–0.67)	0.95 (0.91–0.98)
Modified MEW^a				
SBP <90 mm Hg	17 (36.2)	13 (6.9)	0.36 (0.23–0.51)	0.93 (0.88–0.96)
HR >120	30 (58.8)	12 (6.4)	0.59 (0.44–0.72)	0.94 (0.89–0.97)
RR >30	14 (31.1)	0	0.31 (0.18–0.47)	1.00 (0.98–1.00)
Neurological changes	17 (37.8)	0	0.38 (0.24–0.53)	1.00 (0.98–1.00)
Any MEW trigger	31 (81.6)	24 (13.3)	0.82 (0.66–0.92)	0.87 (0.81–0.91)

SIRS: Systemic Inflammatory Response Syndrome; **MEW:** Maternal Early Warning
qSOFA: quick Sequential (Sepsis Related) Organ Failure Assessment

Sepsis Criteria


	N (%) Sepsis	N (%) Controls	Sensitivity	Specificity
SIRS (Any 2)	40 (93%)	51 (36.7%)	0.93 (0.81-0.99)	0.63 (0.55-0.71)
qSOFA (Any 2)	19 (50%)	9 (5%)	0.50 (0.33-0.67)	0.95 (0.91-0.98)
Modified MEW (Any 1)	31 (81.6%)	24 (13.3%)	0.82 (0.66-0.92)	0.87 (0.81-0.91)

Validated Maternal Sepsis Cases: 1995 to 2012, 78 Cases

Causes: Chorioamnionitis and Endometrosis = 50%

Mortality: Antibiotics < 1 hr, 8.3%; > 1 hr, 20%

○ Mortality Rate for Sepsis/Million Maternities



CDC Pregnancy Mortality 2020; Loudon I. Maternal Mortality 1800-1950. 1992.
Lucas DN, et al. IJOA 2012;21:56-67; Bauer ME, et al. Anesth Analg 2013;117:944-50

Infection Risks: Risk Factors for Sepsis

Obstetric Management

- Amniocentesis/Invasive intrauterine procedures
- Prolonged ROM
- Prolonged labor with >5 vaginal examinations
- Vaginal trauma
- Cervical suture
- Cesarean delivery
- Retained products

Maternal Factors

- Impaired immunity
- Impaired GTT
- Obesity
- Sickle cell anemia (Asplenia)
- Vaginal discharge
- Hx pelvic infection
- Hx GBS infection
- Socioeconomic
- Age


Fetal Factors

- Limited immunity
- Low gestational age
- Febrile (38C)
- ROM duration
- Maternal infection
- GB Strep infection

Sepsis Concerns: Maternal vs. Fetal Needs


Mother

Fetus



Sepsis Concerns: Maternal vs. Fetal Needs

Mother



Fetus

- **Dependence:**
O₂ & perfusion thresholds
- **Competition:**
Gestational milestones
- **Intervention:**
Invasive procedures

Identify Risks To The Fetus

- Infection
- Perfusion
- Oxygenation



Infection Risks

Puerperal Infection (World Health Organization)

Infections of GU system related to labour, delivery, periperium

Uterus and Associated Structures (Chorioamnionitis, Endometritis)

Wound Infection: CD 5-20 x VD, especially if emergent

Urinary Tract

Infections related to the birth

Breast Abscess

Pyelonephritis

Pelvic thrombophlebitis


Incidental Infections

HIV, Pneumonia, TB, Malaria


Concurrent Dx (n=3177)	%
Pneumonia	29.7
GU Infection	29.7
Chorioamnionitis	18.4
Endometritis	8.6
Pyelonephritis	5.8
Wound Infection	4.7

World Health Organization Collaborative Study Team, 2000; Bauer et al. A&A 2013
Bauer ME, Chau MD, Einav S, Leffert L, Toledo P, Tsen LC, Bateman B. A&A 2018

Infection Risks: Pathway to the Fetus



Infection Risks: Pathway to the Fetus



Stage 4
Fetal Infection

Stage 3
Amnionitis

Stage 2
Deciduitis
Chorioamniitis

Stage 1
Vaginal /CervicalFlora

Infection Risks: Fetal Response

Fetal Tachycardia (40-70%)

35 wks **autonomic nervous system** maturity

Fetal Movement


Fetal Inflammatory Response Syndrome

Histologic, rather than clinical, diagnosis


1. Increased systemic **cytokines (IL6)**
2. **Funisitis** (umbilical cord inflammation)
3. **Vasculitis** in the chorion

Associated with Cerebral and Respiratory Pathology

Infection Risks: Fetal Response



Infection Risks: Fetal Response



Risks to the Fetus Perfusion



Uteroplacental Blood Flow

Uterine Blood Flow

Not autoregulated

Maximally dilated


Uterine Vessels

More responsive










to alpha-agonists

Divert to systemic

vasculature/organs



Uteroplacental Blood Flow: Sheep

	Ephedrine a1, b1, b2	Metaraminol a1, b1	Phenylephrine a1, a2
MBP			
UA Flow			
Fetal pH			

Uteroplacental Blood Flow: Human

	Ephedrine	Phenyl + Ephedrine	Phenyl	P Value
V-A pH	0.07	0.07	0.05	0.003
A-V pCO ₂	14	13	11	0.006
UA Base Deficit	-2.2	-1.4	-1.8	0.16
Acidotic Fetuses	10	1	1	


Cooper D, et al. *Anesthesiology* 2002;97:1582-1590
Ngan Kee et al. *Anesthesiology* 2009;111:506-512

Uteroplacental Blood Flow: Human

	Ephedrine	Phenyl + Ephedrine	Phenyl	P Value
V-A pH	0.07	0.07	0.05	0.003
A-V pCO ₂	14	13	11	0.006
UA Base Deficit	-2.2	-1.4	-1.8	0.16
Acidotic Fetuses	10	1	1	


Cooper D, et al. *Anesthesiology* 2002;97:1582-1590
Ngan Kee et al. *Anesthesiology* 2009;111:506-512

Perfusion: Hypotension



Sugerman, 1981

Perfusion: Hypotension on Fetus



Septic Hypotension + Uterine Hypertonus: FHR bradycardia
Shunting of blood from splanchnic (uterine) bed

Perfusion: Hypotension on Fetus

Fetal Biophysical Profile (fetal BPP), 30 min

Normal 8-10; Equivocal <6, repeat in 12-24 hrs


Component	Normal	Score
Nonstress Test	Reactive	2
Fetal Breathing	Duration \geq 1	2
Fetal Movement	\geq 3 Movements	2
Fetal Tone	Flex/Extend Limb	2
Amniotic Fluid Volume	Am Fluid Index $>$ 5 cm	2
Max Score		10

Risks to the Fetus Oxygenation




Oxygenation

Towell ME: Perinatal Med 1976







Oxygenation

$$DO_2 = [1.39 \times Hb \times SaO_2 + (0.003 \times PaO_2)] \times Q$$




Oxygenation



Therapies




California Maternal Quality Care Collaborative Maternal Evaluation Sepsis Flow Chart 2019




Abir G, Bauer M. Maternal Sepsis Update, Current Opinion. 2021

Step 1: Identify and Treat Pathogen

Surviving Sepsis Campaign Clinical Care Bundle/ Grouped Interventions



1. Obtain culture (blood or swab) prior to antibiotics
2. Administer broad spectrum antibiotic within 1 hour



Step 1: Identify and Treat Pathogen

	Gram +			Gram -		Other	
	Cocci	Rods	Acid-Fast	Cocci	Rods	Spiral Rods	Misc
Aerobic	Staph 22.2% Strep 20.1%	Coryne- bacterium			E.Coli 26%		Ureaplasma
Anaerobic		Clostridium Lactobacillis			Bacteroides 2%		

Step 1: Identify and Treat Pathogen

Obtain Blood Cultures Prior to Antibiotics

Unknown Organism, Not Critical

Co-amoxiclav
1.2 g q 8 hrs

Cefotaxime (3rd)
1-2 gm q 8 hrs

Cefuroxime (2nd)
1.5 g q 8 hrs

Metronidazole
500 mg q 8 hrs

If allergic to penicillin or cephalosporins

Clindamycin
600-1200 mg q 6
to 8 hrs

Gentamicin
500 mg q 8 hrs

Clarithromycin
500mg q 12 hrs

Step 1: Identify and Treat Pathogen

Severe Sepsis or Septic Shock

Piperacillin-
Tazobactam
4.5 g q 8 hrs

Gentamicin
3-5 mg/kg daily
divided q 8 hrs

Meropenem
500-1000 mg
q 8 hrs

Ciprofloxacin
600 mg q 12 hrs

Metronidazole
500 mg q 8 hrs

Group A Strep

Clindamycin
600-1200 mg
q 6 to 8 hrs

MRSA Septicemia Risk

Linezolid 600 mg
q 12 hrs

Teicoplanin 10
mg/kg q 12 hrs x 3
doses, then q day

Step 1: Identify and Treat Pathogen

Postpartum Sepsis Workup

	Symptomatic	Asymptomatic
CBC, Blood Culture	X	X
CSF Studies, Chest X-Ray	X	
Empiric Antibiotics	X	

Empiric Antibiotic Risk in Uninfected

Fungal infections, bacterial late onset sepsis, necrotizing enterocolitis, recurrent wheezing disorder at 12 months, death.

Verani JR, et al. Prevention of Perinatal GBS. CDC Revised Guidelines. MMWR 2010

Mukhopadhyay S, Puopolo KM. Risk Assessment in Neonatal Early Onset Sepsis, Sem Perinatol 2012

Step 1: Identify and Treat Pathogen

Postpartum Sepsis Workup

	Term Infants	VLBW (<1500 gm)
Sepsis Cause	Group B Strep	E. Coli
Respiratory, Pressure Support	50%	100%
Death	2-3%	20-30%

Intrapartum Group B Strep Antibiotic Prophylaxis

Neonatal Sepsis: 3-4 to 0.8-1.0 cases/1000 live births

Neonatal GBS Sepsis 0.3-0.4 cases/1000 live births


Verani JR, et al. Prevention of Perinatal GBS. CDC Revised Guidelines. MMWR 2010

Mukhopadhyay S, Puopolo KM. Risk Assessment in Neonatal Early Onset Sepsis, Sem Perinatol 2012

Step 2: Restore Perfusion

MAP, HR, UO
Hematocrit
FHR

CVP, PA, Echo



Shippy et al., 1984, Shoemaker et al. 1990, Lindeborg 1993

Step 2: Restore Perfusion

Parameter	Nonpregnant	Pregnant	Change (%)
CO (L/min)	4.3	6.2	43
HR (bpm)	71	83	17
COP (mmHg)	20.8	18	-14
COP-PCWP	14.5	10.5	-18
SVR (dyne/s/cm ⁵)	1530	1210	-21
PVR (dyne/s/cm ⁵)	119	78	-34
MAP (mmHg)	86.4	90.3	NC
CVP (mmHg)	3.7	3.6	NC
PCWP (mmHg)	6.3	7.5	NC
LVSWI (g/m/m ²)	41	48	NC

Step 2: Restore Perfusion

Hypotension or Lactate > 4 mmol/L

Goals MAP > 65 mmHg CVP > 8 mmHg (12 if ventilated)	Remeasure If Initial Lactate > 2
--	--

Volume Challenge

CO/PCWP/LVSWI

COP-PCWP Gradient

Fluids
Crystal/Colloid

Dwell Time

Crystalloid: 28% at 30 min

Colloid: 100% at 30 min

Roberts, 1971; Hawkins 1980; Kaufman 1984; Ueyama et al. Anesthesiology 1999

www.survivingsepsis.org/Bundles/Pages/default.aspx

Step 2: Restore Perfusion

Hypotension or Lactate > 4 mmol/L

Goals

MAP > 65 mmHg

CVP > 8 mmHg (12 if ventilated)

Maternal Macro/
Microvascular
Shunt v Perfusion
Lactic Acid

Vasopressor
Phenylephrine
NorEpi/Epi

Maternal v Fetal
FHR Tracing

Fluids
Crystal/Colloid

Inotrope
Dopamine
Dobutamine

Hyperdynamic
Ability
CI > 4.5 L/min/m²
DO₂ > 0.6 L/min/m²

Step 3: Improve Oxygenation

Hypotension or Lactate > 4 mmol/L

Goals

MAP > 65 mmHg

CVP > 8 mmHg (12 if ventilated)

Steroids

Vasopressor
Phenylephrine
Norepi/Epi

Oxygen

Fluids
Crystal/Colloid

Inotrope
Dopamine

Hemoglobin
> 7 gm/dL

Step 3: Improve Oxygenation

Hypotension or Lactate > 4 mmol/L

High Dose Steroids

Short term, Superinfections, ARDS
Fetal Pulmonary Maturation

Steroids

Decreased Ability to Extract O₂

Cellular and Mitochondrial Dysfunction
Microvascular Shunting
Autoregulation Loss

Oxygen

Left Shift O₂Hb Dissociation Curve

Hypophosphatemia, Alkalosis, Transfusions

Hemoglobin
> 7 gm/dL

Step 4: Consider Interventions

Magnesium

Fetal neurologic protection

Reduced sepsis mortality (2-3 x)

Magnesium

Histologic Analysis

To determine fetal infection

Cord Sampling

Induction or Cesarean Delivery

Fetus as source of infection

Fetal viability

Delivery

Step 4: Consider Interventions

COVID-19 with mild ARDS	COVID-19 with Mod to Severe ARDS	Rescue/Adjunctive therapy
<p>✓ Do: Vt 4-8 ml/kg and P_{plat} < 30 cm H₂O</p>	<p>⚠ CONSIDER: Higher PEEP</p>	<p>❓ Uncertain: Antivirals, chloroquine, anti-IL6</p>
<p>✓ Do: Investigate for bacterial infection</p>	<p>⚠ CONSIDER: NMBA boluses to facilitate ventilation targets</p>	<p>⚠ CONSIDER: if proning, high P_{plt}, asynchrony NMBA infusion for 24 h</p>
<p>✓ Do: Target SpO₂ 92% - 96%</p>	<p>⚠ CONSIDER: if PEEP responsive Traditional Recruitment maneuvers</p>	<p>⚠ CONSIDER: Prone ventilation 12-16 h</p>
<p>⚠ CONSIDER: Conservative fluid strategy</p>	<p>⚠ CONSIDER: Prone ventilation 12-16 h</p>	<p>⚠ CONSIDER: STOP if no quick response A trial of inhaled Nitric Oxide</p>
<p>⚠ CONSIDER: Empiric antibiotics</p>	<p>⚠ CONSIDER: if proning, high P_{plt}, asynchrony NMBA infusion for 24 h</p>	<p>⚠ CONSIDER: follow local criteria for ECMO V-V ECMO or referral to ECMO center</p>
<p>❓ Uncertain: Systematic corticosteroids</p>	<p>🚫 Don't do: Staircase Recruitment maneuvers</p>	
	<p>⚠ CONSIDER: Short course of systemic corticosteroids</p>	
	<p>❓ Uncertain: Antivirals, chloroquine, anti-IL6</p>	

Fig. 3 Summary of recommendations on the management of patients with COVID-19 and ARDS

Take Home Messages



Take Home Messages

Fetal Optimization During Maternal Sepsis

MEW: Maternal Early Warning

SIRS: Systemic Inflammatory Response Syndrome

qSOFA: quick Sequential Organ Failure Assessment

- **D**efinitions

- **I**dentify **R**isks

- **T**herapies

1. Early & Appropriate Antibiotics
2. Maximize Uteroplacental Flow
3. Minimize Fetal Oxygen Demand
4. Avoid Preterm Delivery
5. Monitor/Intervention



<https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/Adult-Patients>

Stephens AJ, et al. Maternal Sepsis Guidelines, AJ Perinat 2023

